ARTICLE | Emerging Company Profile
Ambagon: creating molecular glues for disordered proteins
Nextech Invest leads $85M series A to make the difficult-to-drug protein class amenable to small molecules
February 2, 2022 1:14 AM UTC
Ambagon has a new approach to a challenging target class: intrinsically disordered proteins. The San Carlos, Calif.-based start-up is forcing disordered proteins to acquire a druggable interface using molecular glues to stabilize their interaction with a signaling hub.
Fresh off his CEO experience at Tizona Therapeutics Inc., Scott Clarke joined Ambagon Therapeutics Inc. as CEO in February 2021...
BCIQ Company Profiles